Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 1/20 | 0.48 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.48 |
| ▸ | ITGAL | P20701 | 1/20 | 0.48 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.42 |
| ▸ | PTPRA | P18433 | 1/20 | 0.42 |
| ▸ | NQO2 | P16083 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13814414 | 0.76 | TACR1 (0.45) | — | |
| SCHEMBL4442998 | 0.76 | CTSL (0.45) | ITGB2ICAM1ITGALNQO2 | |
| SCHEMBL4113363 | 0.75 | MEN1 (0.37) | ITGB2ICAM1ITGALMMP2 | |
| SCHEMBL4167934 | 0.75 | CCKBR (0.44) | — | |
| SCHEMBL8251395 | 0.75 | SCN9A (0.45) | ITGB2ICAM1ITGALMMP2 | |
| SCHEMBL4104230 | 0.74 | DPP4 (0.49) | ITGB2ICAM1ITGALPTPRANQO2 | |
| SCHEMBL4179156 | 0.74 | DPP4 (0.49) | ITGB2ICAM1ITGALPTPRANQO2 | |
| SCHEMBL4179160 | 0.74 | DPP4 (0.49) | ITGB2ICAM1ITGALPTPRANQO2 | |
| Trifluoroacetic Acid SCHEMBL4165385 | 0.71 | DPP4 (0.47) | PTPRANQO2CYP2C19 | |
| SCHEMBL4106136 | 0.69 | SCN9A (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090149504-A1 | Novel 5-Substituted Indole Derivatives As Dipeptidyl Peptidase IV (DPP-IV) Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149504-A1 | Novel 5-Substituted Indole Derivatives As Dipeptidyl Peptidase IV (DPP-IV) Inhibitors | DPP4, DPP3, DPP7 | ITGB2 4711/4885ICAM1 2626/4885ITGAL 4098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.